Literature DB >> 3390350

Uptake of indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma.

D J Macey1, S J Denardo, G L Denardo, J K Goodnight, M W Unger.   

Abstract

The accumulation of an Indium-111-labeled monoclonal antibody (MoAb), ZME-018, in melanoma tumors in a patient was determined by sequential, quantitative gamma camera imaging. The amount and concentration of In-111 in each tumor changed in a characteristic pattern with time, reaching a peak at day 3 followed by a steady clearance. The concentration of In-111 in the tumor and the ratios of tumor to whole-body or blood decreased as the size of the tumor increased. These results were interpreted to indicate that the fraction of active, perfused tumor decreased as the melanoma lesions increased in size. The maximum number of MoAb molecules bound per melanoma cell was calculated to be abut 35,000. The implications of these observations for radioimmunoimaging and therapy are significant.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3390350

Source DB:  PubMed          Journal:  Am J Physiol Imaging        ISSN: 0885-8276


  9 in total

1.  Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.

Authors:  Hong Zhou; Yuying Liu; Lawrence H Cheung; Sehoon Kim; Weihe Zhang; Khalid A Mohamedali; Preetha Anand; Walter N Hittelman; Bharat B Aggarwal; Michael G Rosenblum
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.

Authors:  Yuying Liu; Weihe Zhang; Lawrence H Cheung; Ting Niu; Qingping Wu; Chun Li; Carolyn S Van Pelt; Michael G Rosenblum
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

3.  Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy.

Authors:  R W Howell; S M Goddu; D V Rao
Journal:  Med Phys       Date:  1998-01       Impact factor: 4.071

4.  Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma Cells.

Authors:  Christopher Scott Berger; John W Marks; Robert D Bolskar; Michael G Rosenblum; Lon J Wilson
Journal:  Transl Oncol       Date:  2011-12-01       Impact factor: 4.243

5.  Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity.

Authors:  Yuying Liu; Weihe Zhang; Ting Niu; Lawrence H Cheung; Anupama Munshi; Raymond E Meyn; Michael G Rosenblum
Journal:  Neoplasia       Date:  2006-02       Impact factor: 5.715

6.  Targeted radionuclide therapy.

Authors:  Lawrence E Williams; Gerald L DeNardo; Ruby F Meredith
Journal:  Med Phys       Date:  2008-07       Impact factor: 4.071

7.  Quantitative measurement of uptake of radiolabeled monoclonal antibody by means of planar data.

Authors:  Y Akiyama; N Yui; T Matsumoto; T A Iinuma; H Ikehira; H Fukuda; Y Tateno
Journal:  Ann Nucl Med       Date:  1991-03       Impact factor: 2.668

8.  Differences in biodistribution of the anti-(carcinoembryonic antigen) murine monoclonal antibody CE-25, its F(ab')2 fragment and its intact mainly human chimeric form CE 4-8-13. Dependence on tumour size and amount of antibody injected.

Authors:  G Westera; T Rülicke; A Smith; S Duewell
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

9.  Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.

Authors:  Liza Lindenberg; Anish Thomas; Stephen Adler; Esther Mena; Karen Kurdziel; Julia Maltzman; Bruce Wallin; Kimberly Hoffman; Ira Pastan; Chang Hum Paik; Peter Choyke; Raffit Hassan
Journal:  Oncotarget       Date:  2015-02-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.